SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Analysts and Calls -- Lehman

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (22)4/4/2003 11:54:12 AM
From: tuck   of 30
 
Birchenough and I disagree on CTIC:

>>Lehman Brothers analyst Jim Birchenough believes Cell Therapeutics is a better-run company with the new employees brought in, especially those on the clinical side. But, he acknowledges, "It would have been better for [Cell Therapeutics] to be as open and public as possible about the upgrade of personnel." He rates Cell Therapeutics overweight and his firm doesn't do banking for the company.<<

Snipped from Street.com Feuerstein piece. So far, Birchenough is winning.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext